Page 6 - M.Hofman-Session3
P. 6

LEARNING OBJECTIVES







          By participating in this webinar, participants can expect to:






          ▪ Understand rationale combinations of                                 177  Lu-PSMA currently under

                evaluation in clinical trials


          ▪ Discuss the possible mechanisms of resistance with                                          177 Lu-PSMA


          ▪ Review the role of alpha emitters including Radium-223


          ▪ Discuss if          177  Lu-PSMA should be used as an earlier line of treatment
   1   2   3   4   5   6   7   8   9   10   11